APC/Cyanine7 anti-mouse CD279 (PD-1) Antibody
- 产品名称：
- APC/Cyanine7 anti-mouse CD279 (PD-1) Antibody
- 产品类别：
- 抗体
- 产品编号：
- 135223
- 产品应用：
- 135223
- Verified Reactivity
- Mouse
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- PD-1 cDNA followed by PD-1-Ig fusion protein
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
- Preparation
- The antibody was purified by affinity chromatography and conjugated with APC/Cyanine7 under optimal conditions.
- Concentration
- 0.2 mg/ml
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.06 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.
- Excitation Laser
- Red Laser (633 nm)
- Application Notes
Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.
- Additional Product Notes
BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.
- Application References
(PubMed link indicates BioLegend citation) -
- Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
- Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
- Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
- Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
- Radtke?AJ,?et al.?2020.?Proc Natl Acad Sci U S A.?117:33455-65. (SB)?PubMed
- Radtke?AJ,?et al.?2022.?Nat Protoc.?17:378-401. (SB)?PubMed
- Product Citations
-
- Xu W et al. 2019. Immunity. 50(4):1054-1068 . PubMed
- Ersching J et al. 2017. Immunity. 46(6):1045-1058 . PubMed
- Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed
- Snell LM, et al. 2018. Immunity. 49:678. PubMed
- Li J, et al. 2018. Immunity. 49:178. PubMed
- Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
- Mender I, et al. 2020. Cancer Cell. 38(3):400-411.e6. PubMed
- Leclerc M, et al. 2019. Nat Commun. 10:3345. PubMed
- Zhou J, et al. 2022. Int J Oncol. 61:. PubMed
- Andersen TK, et al. 2019. NPJ Vaccines. 4:9. PubMed
- Fedele C, et al. 2021. J Exp Med. 218: . PubMed
- Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
- Mesin L, et al. 2020. Cell. 180(1):92-106.e11.. PubMed
- Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
- RRID
- AB_2563522 (BioLegend Cat. No. 135223) AB_2563523 (BioLegend Cat. No. 135224)
- Structure
- A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
- Distribution
-
Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.
- Function
- Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
- Ligand/Receptor
- B7-H1 (PD-L1) and B7-DC (PD-L2)
- Cell Type
- B cells, T cells
- Biology Area
- Cancer Biomarkers, Immunology, Inhibitory Molecules
- Molecular Family
- CD Molecules, Immune Checkpoint Receptors
- Antigen References
-
1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313
- Gene ID
- 18566 View all products for this Gene ID
- UniProt
- View information about CD279 on UniProt.org
